Open AccessOsteonecrosis of the jaw: BRONJ and ARONJ
Author(s) -
Salvatore L. Ruggiero
Publication year - 2014
Publication title -
faculty dental journal
Language(s) - English
Resource type - Journals
eISSN - 2042-6860
pISSN - 2042-6852
DOI - 10.1308/rcsfdj.2014.5.2.90
Subject(s) - osteonecrosis of the jaw , osteoclast , medicine , osteoporosis , bone resorption , complication , dentistry , resorption , jaw bone , quality of life (healthcare) , bisphosphonate , surgery , implant , receptor , nursing
Bisphosphonates and other more recent antiresorptive agents are potent inhibitors of osteoclast function and osteoclast-mediated bone resorption. As such, they have been effectively utilised to reduce skeletally related events and improve the quality of life of patients with osteoporosis and malignant osteolytic disease. Despite these benefits, osteonecrosis of the jaw continues to be a worrisome complication in a small subset of patients receiving these drugs.